The Lancet Haematology in conversation with

The Lancet Haematology in conversation with

By The Lancet GroupMedicineHealth & Fitness
Download on the App Store

The Lancet Haematology in conversation with episodes

  • Thalassaemia revisited: from health burden to breakthroughs

    Thalassaemia care is advancing fast, from gene therapies to AI diagnostics, but access and prevention still lag behind. Hear from the authors of The Lancet Haematology's "Thalassaemia revisited: from health burden to breakthroughs" Series, produced with The Lancet Regional Health – Southeast Asia, on epidemiology across Asia, what's working in prevention, the real barriers to gene therapy access, and what's next for hydroxyurea, regional manufacturing, and AI in patient care.

    Click here to visit the series Hub page: 

    www.thelancet.com/series-do/thalassaemia

    Or read the full articles from:

    The Lancet Regional Heath Southeast Asia:  https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00148-4/fulltext

    and
    https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00095-8/fulltext

    The Lancet Haematology:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00173-0/fulltext
    and
    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00197-3/fulltext

    The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

    Find the best science for better lives at www.thelancet.com


    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    49 min
  • Adverse event reporting in haematological malignancies with the authors of our Adverse Events Series

    Blood cancer treatments are advancing fast — but so are their side effects. Hear from the authors of The Lancet Haematology's Adverse Event reporting series on better trial design, patient-centric care, and what part 2 (2026) reveals about long-term toxicity, survivorship, regulation, and digital health tools.

    Click here to visit the series hub on thelancet.com:

    https://www.thelancet.com/series-do/adverse-events-in-haematology-oncology

    The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

    Find the best science for better lives at www.thelancet.com


    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    36 min
  • Bethany Samuelson Bannow and Maureen Achebe on classical haematological disease in women

    Dr Lan-Lan Smith joined the lead author of our latest Commission Dr Bethany Samuelson Bannow and author Dr Maureen Achebe to discuss classical haematological disease in women with Dr Julia Sandrin Gauer from the Intenational Society on Thrombosis and Haemostasis. The podcast was recorded and produced by the ISTH to coincide with the launch of the Commission at the ISTH congress in Paris in July 2026.

    Click here to read the commission on thelancet.com:

    https://www.thelancet.com/commissions-do/women-bleeding-thrombosis

    The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

    Find the best science for better lives at www.thelancet.com


    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    25 min
  • Fabio Efficace and Alice Di Rocco on patient-reported outcomes following CAR T-cell therapy

    Most previous patient-reported outcome results for CAR T-cell therapy have come from clinical trials testing these treatments, but information on how patients experience this treatment in real-world settings is scarce.

    Dr Fabio Efficace and Dr Alice Di Rocco discuss their recent prospective study to measure real-world patient-reported symtomatic adverse events in those receiving CAR T-cell therapy for aggressive B-cell lymphomas, and how these outcomes match those reported by the physicans treating the patients. They discuss some of the rich and varied findings that they uncovered from their study.

    Click here to read the full article:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00128-6/fulltext

    The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

    Find the best science for better lives at www.thelancet.com


    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    16 min
  • Carmelo Gurnari on the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee

    Dr Carmelo Gurnari joins us to discuss the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee on diagnosis, prevention, treatment, and donor management of donor cell-derived haematological neoplasms after HCT

    click here to read the full article:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00046-3/fulltext

    The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

    Find the best science for better lives at www.thelancet.com


    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    18 min
  • Penelope Stein on acute prophyria

    Dr Penelope Stein joins us to discuss the development of new international guidelines for the diagnosis, management, and treatment of the rare, genetically-linked condition, acute prophyria.

    Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00044-X/fulltext

    The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

    Find the best science for better lives at www.thelancet.com


    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    17 min
  • Marc Riedl on hereditary angioedema

    Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for prophylaxis of attacks.

    Click here to read the full articles:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00341-2/fulltext 

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00004-9/fulltext

    Continue this conversation on social!

    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

    Find the best science for better lives at www.thelancet.com


    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    18 min
  • Julio Delgado and Valentín Ortiz-Maldonado (Spanish version)

    Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain.

    Click here to read the full article:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext

    English version of this podcast:

    https://www.buzzsprout.com/1564352/episodes/18730659

    Continue this conversation on social!

    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

    Find the best science for better lives at www.thelancet.com


    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    13 min
  • Julio Delgado and Valentín Ortiz-Maldonado

    Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain.

    Click here to read the full article:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext

    Continue this conversation on social!

    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

    Find the best science for better lives at www.thelancet.com


    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    13 min
  • Erica Kaye and Dylan Graetz discuss expert recommendations for the conduct and appraisal of qualitative research in haematology

    Dr Erica Kaye and Dr Dylan Graetz join us to discuss the importance of qualitative research and how the whole research ecosystem can incorporate and support this type of research to help set the right research questions, and promote the patient voice.

    Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00321-7/fulltext

    Continue this conversation on social!

    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

    Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

    Podcast editing: Matteo Simonetti

    Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

    Find the best science for better lives at www.thelancet.com


    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    20 min

About The Lancet Haematology in conversation with

From the publisher's feed

Lan-Lan Smith, Editor-in-Chief, Emma Cookson, Deputy Editor, and Daniela Marín, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and…

More shows like The Lancet Haematology in conversation with

The Lancet Voice by The Lancet Group

The Lancet Voice

21 Listeners

The Lancet Child & Adolescent Health in conversation with by The Lancet Group

The Lancet Child & Adolescent Health in conversation with

0 Listeners

The Lancet Digital Health in conversation with by The Lancet Group

The Lancet Digital Health in conversation with

0 Listeners

The Lancet Global Health in conversation with by The Lancet Group

The Lancet Global Health in conversation with

2 Listeners

The Lancet Oncology in conversation with by The Lancet Group

The Lancet Oncology in conversation with

1 Listeners

The Lancet Psychiatry in conversation with by The Lancet Group

The Lancet Psychiatry in conversation with

0 Listeners

The Lancet Respiratory Medicine in conversation with by The Lancet Group

The Lancet Respiratory Medicine in conversation with

1 Listeners

The Lancet in conversation with by The Lancet Group

The Lancet in conversation with

0 Listeners

The Lancet Gastroenterology & Hepatology in conversation with by The Lancet Group

The Lancet Gastroenterology & Hepatology in conversation with

0 Listeners

The Lancet Diabetes & Endocrinology in conversation with by The Lancet Group

The Lancet Diabetes & Endocrinology in conversation with

1 Listeners

The Lancet Infectious Diseases in conversation with by The Lancet Group

The Lancet Infectious Diseases in conversation with

0 Listeners

The Lancet Public Health in conversation with by The Lancet Group

The Lancet Public Health in conversation with

1 Listeners

The Lancet Microbe in conversation with by The Lancet Group

The Lancet Microbe in conversation with

0 Listeners

eBioMedicine in conversation with by The Lancet Group

eBioMedicine in conversation with

0 Listeners

In conversation with... by The Lancet Neurology

In conversation with...

0 Listeners

The Lancet Rheumatology in conversation with by The Lancet Group

The Lancet Rheumatology in conversation with

0 Listeners

The Lancet Regional Health Western Pacific in conversation with by The Lancet Group

The Lancet Regional Health Western Pacific in conversation with

0 Listeners

The Lancet Primary Care in conversation with by The Lancet Group

The Lancet Primary Care in conversation with

0 Listeners

The Lancet Regional Health Americas in conversation with by The Lancet Group

The Lancet Regional Health Americas in conversation with

0 Listeners